CN116723836A - 用于治疗急性心房颤动的舒欣啶施用 - Google Patents

用于治疗急性心房颤动的舒欣啶施用 Download PDF

Info

Publication number
CN116723836A
CN116723836A CN202180055470.6A CN202180055470A CN116723836A CN 116723836 A CN116723836 A CN 116723836A CN 202180055470 A CN202180055470 A CN 202180055470A CN 116723836 A CN116723836 A CN 116723836A
Authority
CN
China
Prior art keywords
administration
pharmaceutically acceptable
acceptable salt
cmax
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180055470.6A
Other languages
English (en)
Chinese (zh)
Inventor
加里·艾略特
米雷耶·吉林斯
罗伯特·古德诺
杰·梅森
瓦尔德马·拉兹泽夫斯基
苏珊妮·罗马诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huya Biological International Co ltd
Original Assignee
Huya Biological International Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Biological International Co ltd filed Critical Huya Biological International Co ltd
Publication of CN116723836A publication Critical patent/CN116723836A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180055470.6A 2020-06-12 2021-06-11 用于治疗急性心房颤动的舒欣啶施用 Pending CN116723836A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063038664P 2020-06-12 2020-06-12
US63/038,664 2020-06-12
PCT/US2021/037098 WO2021252959A1 (en) 2020-06-12 2021-06-11 Sulcardine administration for treatment of acute atrial fibrillation

Publications (1)

Publication Number Publication Date
CN116723836A true CN116723836A (zh) 2023-09-08

Family

ID=78824214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180055470.6A Pending CN116723836A (zh) 2020-06-12 2021-06-11 用于治疗急性心房颤动的舒欣啶施用

Country Status (14)

Country Link
US (2) US11813245B2 (https=)
EP (1) EP4164633A4 (https=)
JP (1) JP2023529196A (https=)
KR (1) KR20230024347A (https=)
CN (1) CN116723836A (https=)
AU (1) AU2021288056A1 (https=)
BR (1) BR112022025216A2 (https=)
CA (1) CA3182015A1 (https=)
CL (1) CL2022003501A1 (https=)
CO (1) CO2023000194A2 (https=)
IL (1) IL298907A (https=)
MX (1) MX2022015834A (https=)
PH (1) PH12022553396A1 (https=)
WO (1) WO2021252959A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869357A (zh) * 2009-11-17 2013-01-09 沪亚生物国际有限责任公司 舒欣啶及其盐的缓慢滴注
CN104324024A (zh) * 2009-11-17 2015-02-04 沪亚生物国际有限责任公司 心房纤颤的治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1172908C (zh) * 1999-12-10 2004-10-27 中国科学院上海药物研究所 N-取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
CN113453677A (zh) * 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) * 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102869357A (zh) * 2009-11-17 2013-01-09 沪亚生物国际有限责任公司 舒欣啶及其盐的缓慢滴注
CN104324024A (zh) * 2009-11-17 2015-02-04 沪亚生物国际有限责任公司 心房纤颤的治疗
CN105362264A (zh) * 2009-11-17 2016-03-02 沪亚生物国际有限责任公司 心房纤颤的治疗

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MASON J W，等: "HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation-Phase 1 Study Results", 2019年美国心脏病协会（AHA）年会, 16 November 2019 (2019-11-16), pages 1, XP093010864 *
MASON J W，等: "HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation-Phase 1 Study Results", CIRCULATION, vol. 140, no. 1, 11 November 2019 (2019-11-11) *
QIAN CHEN;等: "Pharmacokinetics, safety, and tolerability of sulcardine sulfate: an open-label, single-dose, randomized study in healthy Chinese subjects", FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 31, no. 01, 7 September 2016 (2016-09-07), pages 120 - 125 *
陈玲;等: "全球心血管药物研发动态", 中国新药杂志, vol. 19, no. 01, 15 January 2010 (2010-01-15), pages 8 - 16 *

Also Published As

Publication number Publication date
CO2023000194A2 (es) 2023-03-27
PH12022553396A1 (en) 2024-04-22
JP2023529196A (ja) 2023-07-07
MX2022015834A (es) 2023-04-04
CL2022003501A1 (es) 2023-06-09
KR20230024347A (ko) 2023-02-20
WO2021252959A1 (en) 2021-12-16
US20240058304A1 (en) 2024-02-22
IL298907A (en) 2023-02-01
CA3182015A1 (en) 2021-12-16
EP4164633A4 (en) 2024-07-31
EP4164633A1 (en) 2023-04-19
US12465587B2 (en) 2025-11-11
US11813245B2 (en) 2023-11-14
BR112022025216A2 (pt) 2023-04-04
US20210386708A1 (en) 2021-12-16
AU2021288056A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
RU2334513C2 (ru) Фармацевтические композиции, включающие валсартан и ингибиторы нейтральной эндопептидазы (nep)
US12357611B2 (en) Sulcardine administration for treatment of acute atrial fibrillation
US20080153840A1 (en) Reduction of cardiovascular symptoms
US20250042964A1 (en) Method of treating nash using a long-acting mutant human fibroblast growth factor
KR20160108611A (ko) 심방세동의 치료 방법
JP2013529654A (ja) レボカルニチン及びドベシレートを含む医薬組成物
US20110124724A1 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for regulating the potasium level in the blood
US20110166221A1 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardioversion
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
CN116723836A (zh) 用于治疗急性心房颤动的舒欣啶施用
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
KR102684334B1 (ko) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
HK40061591A (en) Sulcardine administration for treatment of acute atrial fibrillation
US20260041665A1 (en) J-Tp Protection
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
EA045624B1 (ru) Введение сулькардина для лечения острой фибрилляции предсердий
WO2024086819A2 (en) Diagnosis and treatment of heart failure
EP2387996A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of cardiovascular events in patients with permanent atrial fibrillation
HK1155668A (en) Dronedarone for the prevention of permanent atrial fibrillation
HK1117735A (en) Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230908